Employee drug diversion inside a pharmacy rarely announces itself with one dramatic event. It surfaces as a discrepancy in a perpetual inventory count, a gap between what an automated dispensing cabinet logs and what remains on the shelf, or a dispensing pattern that does not match a pharmacist's caseload. Once a pharmacist-in-charge has reason to suspect an employee, the pharmacy is running against a one-business-day federal notification deadline that starts at discovery, and the record built in the first days often decides whether the pharmacy or a single employee ends up in DEA's sights.
Detection Controls: Perpetual Inventory and Dispensing Pattern Review
DEA's security regulations at 21 CFR 1301.71 require every registrant to maintain effective controls and procedures to guard against theft and diversion of controlled substances, and DEA treats a pharmacy's own detection systems as evidence those controls work. For Schedule II substances, standard practice is a perpetual, running inventory reconciled at every shift change, with the physical count verified against the log, a discipline known as inventory reconciliation. A distributor-facing suspicious order monitoring program controls what enters the pharmacy from a wholesaler; it does not catch a substance that leaves through an employee once on the shelf, a distinction covered in Suspicious Order Monitoring: What DEA Expects From Registrants. Dispensing pattern review closes that gap, and the anomalies worth escalating are catalogued in Red Flags in Controlled Substance Dispensing: The Resolution Record.
Opening an Internal Investigation
An internal investigation should start by securing records before the suspected employee can alter them: automated dispensing cabinet access logs, pharmacy video coverage, perpetual inventory records, and the schedule showing who had access during the loss window. Restricting one employee's access while the investigation proceeds is a personnel decision, not a substitute for the reporting obligations below. Employees under investigation are sometimes pressured to voluntarily surrender a DEA registration or state license; before anyone signs, see DEA Voluntary Surrender Forms: Read Before You Sign, because a surrender signed under pressure can foreclose defenses the pharmacy will need later.
The Federal Reporting Clock: DEA Form 106
Federal law requires a registrant to notify its local DEA Diversion Field Office in writing within one business day of discovering a theft or significant loss of controlled substances, a duty set out at 21 CFR 1301.76(b) and 21 U.S.C. 830(b)(1)(C). Every theft must be reported regardless of quantity. A loss that is not clearly theft is reportable only if significant, and DEA's guidance points registrants to the quantity relative to the business, whether the loss ties to a specific employee, and whether losses form a pattern over time. Under DEA's 2023 final rule, the registrant then has 45 days from discovery to file a completed DEA Form 106 electronically, a deadline that does not pause if the drugs are later recovered or the employee is identified.
State Board Reporting Runs on Its Own Track
The DEA Form 106 fails to satisfy a separate duty many state boards of pharmacy impose on the pharmacist-in-charge: reporting suspected diversion by a licensed pharmacist or registered technician to the board itself, often on a shorter clock than DEA's significant-loss standard. A pharmacy that treats the federal filing as the end of its reporting duty can face a board complaint for a report it never made, on top of whatever DEA does with the Form 106.
The pharmacy that reconciles its inventory every shift catches diversion before DEA does.
Why Early Legal Counsel Is Critical
It is critical that a pharmacist-in-charge retain experienced healthcare defense counsel as soon as employee diversion is suspected, not after the Form 106 is filed or a board complaint arrives. Early legal intervention shapes what goes into the theft or loss report and helps avoid admissions DEA could use to argue the pharmacy itself failed to maintain effective controls against diversion, the finding DEA cites when it pursues a DEA order to show cause or, if it finds imminent danger to public health, an immediate suspension order against the pharmacy's own registration. Delaying counsel until an agent is already asking questions narrows the options available at discovery.
How Health Law Alliance Can Help
Health Law Alliance represents pharmacies and pharmacists-in-charge through employee diversion investigations, from the initial DEA Form 106 filing through any order to show cause or immediate suspension order that follows, as part of the firm's DEA defense practice. If your pharmacy has identified a diversion loss and needs the internal investigation, the federal reporting, and the state board notice handled on the correct timeline, contact us for a free, confidential consultation.
